Novo Nordisk A/S (NYSE:NVO) Receives Consensus Rating of "Hold" from Analysts

Key Points

• Consensus: Hold — Twenty‑three analysts cover Novo Nordisk with a consensus "Hold" rating (1 sell, 18 hold, 4 buy) and an average 12‑month price target of $65.56.
• Recent results and valuation: shares near $41.19 with a market cap of $183.9B and a P/E of 11.87; the company beat quarterly estimates (EPS $1.01 vs. $0.90; revenue $12.43B vs. $11.97B) and has a dividend payout ratio of ~50.4%.
• Key catalysts and risks: late‑stage pipeline wins and an active DKK 15bn share buyback support upside, while strong Wegovy oral uptake faces competitive pressure from Eli Lilly's new oral obesity drug, posing market‑share and pricing risks.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) has been assigned a consensus recommendation of "Hold" from the twenty-three analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, eighteen have assigned a hold rating and four have issued a buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $65.5625.

A number of brokerages have recently issued reports on NVO. The Goldman Sachs Group reissued a "neutral" rating and issued a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Wolfe Research began coverage on shares of Novo Nordisk A/S in a report on Thursday, March 26th. They issued a "peer perform" rating on the stock. Zacks Research raised shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, March 10th. Citigroup began coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 27th. They issued a "neutral" rating on the stock. Finally, Morgan Stanley raised shares of Novo Nordisk A/S from an "underweight" rating to an "equal weight" rating and set a $40.00 price target on the stock in a report on Tuesday, March 3rd.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $41.19 on Tuesday. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $183.89 billion, a PE ratio of 11.87, a P/E/G ratio of 9.80 and a beta of 0.73. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $81.44. The company has a 50-day moving average price of $38.97 and a two-hundred day moving average price of $47.52.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The firm had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. Equities analysts forecast that Novo Nordisk A/S will post 3.34 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The business also recently announced a dividend, which was paid on Wednesday, April 8th. Investors of record on Monday, March 30th were paid a $1.2751 dividend. This represents a yield of 723.0%. The ex-dividend date of this dividend was Monday, March 30th. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 50.43%.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: U.S. FDA granted Fast Track designation for coramitug (PRX004) in ATTR amyloidosis with cardiomyopathy, and Novo reported positive pivotal Phase 3 HIBISCUS results for etavopivat in sickle cell disease — these expand Novo Nordisk’s late‑stage pipeline beyond GLP‑1s, improving long‑term growth optionality and valuation support. Novo Nordisk Rare Disease Wins Add Context To Undervalued Share Price
• Positive Sentiment: Company continues active capital return with an ongoing share repurchase programme (part of up to DKK 15bn over 12 months), which supports EPS and can prop up the share price. Novo Nordisk A/S - share repurchase programme
• Positive Sentiment: Wegovy oral is maintaining strong prescription momentum — Citi/IQVIA data show the tablet’s scripts roughly double Lilly’s oral competitor at comparable launch stage, supporting continued revenue from the flagship obesity franchise. GLP-1 pill race heats up as Wegovy tablet holds strong against Lilly rival
• Neutral Sentiment: Management is moving into AI partnerships/strategies that could improve R&D productivity over time; the near‑term impact on revenue is uncertain but relevant for long‑range pipeline and cost efficiency expectations. Is This Deal a Game Changer for Novo Nordisk?
• Negative Sentiment: Competitive pressure from Eli Lilly’s new oral weight‑loss drug (Foundayo) is accelerating — early prescription uptake for Foundayo and analysts highlighting future combo therapies raise the risk of market share erosion and price/volume pressure for Novo’s obesity products. Eli Lilly and Company’s (LLY) Foundayo Gets Prescribed 3,707 Times in the US in Second Week of Launch, Reuters Reports
• Negative Sentiment: Broader industry moves (analyst comparisons with Pfizer, new diabetes entrants like Alnylam) highlight strategic tradeoffs: Novo must defend GLP‑1 leadership while funding diversification — a mixed near‑term growth outlook that can weigh on multiples. Novo Nordisk vs. Pfizer: Which Healthcare Giant Is the Better Bet?

Institutional Investors Weigh In On Novo Nordisk A/S

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Lafayette Investments Inc. raised its stake in Novo Nordisk A/S by 4.8% in the first quarter. Lafayette Investments Inc. now owns 72,455 shares of the company's stock valued at $2,663,000 after purchasing an additional 3,317 shares in the last quarter. Simplify Asset Management Inc. purchased a new stake in Novo Nordisk A/S in the first quarter valued at approximately $12,030,000. Sierra Ocean LLC raised its stake in Novo Nordisk A/S by 22.9% in the first quarter. Sierra Ocean LLC now owns 6,825 shares of the company's stock valued at $251,000 after purchasing an additional 1,270 shares in the last quarter. World Investment Advisors raised its stake in Novo Nordisk A/S by 12.0% in the first quarter. World Investment Advisors now owns 15,010 shares of the company's stock valued at $552,000 after purchasing an additional 1,607 shares in the last quarter. Finally, PAX Financial Group LLC raised its stake in Novo Nordisk A/S by 87.0% in the first quarter. PAX Financial Group LLC now owns 13,940 shares of the company's stock valued at $512,000 after purchasing an additional 6,487 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.